BrainStorm Reschedules First Quarter 2025 Financial Results Release to Post-Market Close Today and Sets Investor Call for Monday, May 19

Rhea-AI Summary

BrainStorm Cell Therapeutics (NASDAQ: BCLI) has rescheduled its Q1 2025 financial results release to post-market close on May 15, 2025, with an investor conference call now set for Monday, May 19, 2025, at 8:30 a.m. ET. The call will feature CEO Chaim Lebovits presenting a corporate update, joined by COO Haro Hartounian, CMO Bob Dagher, and Interim CFO Alla Patlis.

BrainStorm is developing adult stem cell therapies for neurodegenerative diseases, with its flagship NurOwn® platform using autologous mesenchymal stem cells to produce neurotrophic factor-secreting cells. The company has completed a Phase 3 trial for ALS and is preparing to launch a confirmatory Phase 3b trial under an FDA Special Protocol Assessment agreement. Additionally, BrainStorm has completed a Phase 2 trial for progressive MS and is advancing an allogeneic exosome-based platform.

NEW YORK, May 15, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it has rescheduled the release of its financial results for the first quarter ended March 31, 2025, to post-market close today, May 15. In addition, the Company has rescheduled its previously announced investor conference call, which will now take place on Monday, May 19, 2025, at 8:30 a.m. Eastern Time.

BrainStorm's President & Chief Executive Officer, Chaim Lebovits, will present a corporate update to be followed by Q&A. Joining Mr. Lebovits to answer investment community questions will be Haro Hartounian, Ph.D., Chief Operating Officer, Bob Dagher, M.D., Chief Medical Officer, and Alla Patlis, CPA, MBA, Interim Chief Financial Officer.

Participants are encouraged to submit their questions in advance of the call by sending them to: q@brainstorm-cell.com. Questions should be submitted by 5:00 p.m. Eastern Time on Friday, May 16, 2025.

Investors may access the conference call by dialing the following numbers:

Participant Numbers:

Toll Free	888-506-0062
International	973-528-0011
Participant Access Code	621608
Webcast	https://www.webcaster4.com/Webcast/Page/2354/52457

The replay of the conference call can be accessed by dialing the numbers below and will be available for 14 days.

Replay Numbers:

Toll Free	877-481-4010
International	919-882-2331
Reply Passcode	52457

About Brainstorm Cell Therapeutics Inc.              
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) is a leading developer of autologous adult stem cell therapies for debilitating neurodegenerative diseases. The company's proprietary NurOwn® platform uses autologous mesenchymal stem cells (MSCs) to produce neurotrophic factor-secreting cells (MSC-NTF cells), designed to deliver targeted biological signals that modulate neuroinflammation and promote neuroprotection.           
NurOwn® is BrainStorm's lead investigational therapy for amyotrophic lateral sclerosis (ALS) and has received Orphan Drug designation from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). A Phase 3 trial in ALS (NCT03280056) has been completed, and a confirmatory Phase 3b trial is set to launch under a Special Protocol Assessment (SPA) agreement with the FDA. The NurOwn clinical program has generated valuable insights into ALS disease biology, including pharmacogenomic response associated with the UNC13A genotype, biomarker data collected at seven longitudinal time points, and a comprehensive analysis of the "Floor Effect" — a critical challenge in measuring clinical outcomes in advanced ALS. BrainStorm has published its findings in multiple peer-reviewed journals. In addition to ALS, BrainStorm has completed a Phase 2 open-label multicenter trial (NCT03799718) of MSC-NTF cells in progressive multiple sclerosis (MS), supported by a grant from the National MS Society. BrainStorm is also advancing a proprietary, allogeneic exosome-based platform designed to deliver therapeutic proteins and nucleic acids. The company recently received a Notice of Allowance from the U.S. Patent and Trademark Office for a foundational patent covering its exosome technology, further strengthening BrainStorm's growing IP portfolio in this emerging area of regenerative medicine.To learn more, visit www.brainstorm-cell.com.

Notice Regarding Forward-Looking Statements 
This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties, including statements regarding meetings with the U.S. Food and Drug Administration (FDA), Special Protocol Assessment (SPA), ADCOM meeting related to NurOwn, the timing of a PDUFA action date for the BLA for NurOwn, the clinical development of NurOwn as a therapy for the treatment of ALS, the future availability of NurOwn to patients, and the future success of BrainStorm. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will" "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on BrainStorm's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. These potential risks and uncertainties include, without limitation, management's ability to successfully achieve its goals, BrainStorm's ability to raise additional capital, BrainStorm's ability to continue as a going concern, prospects for future regulatory approval of NurOwn, whether BrainStorm's future interactions with the FDA will have productive outcomes, and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations, and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements.

CONTACTS

Investors:
Michael Wood
Phone: +1 646-597-6983
mwood@lifesciadvisors.com

Logo - https://mma.prnewswire.com/media/1166536/BrainStorm_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/brainstorm-reschedules-first-quarter-2025-financial-results-release-to-post-market-close-today-and-sets-investor-call-for-monday-may-19-302456403.html

SOURCE BrainStorm Cell Therapeutics Inc.

FAQ

When will BCLI release its Q1 2025 financial results?

BrainStorm Cell Therapeutics will release its Q1 2025 financial results after market close on May 15, 2025.

When is BrainStorm's (BCLI) Q1 2025 earnings call scheduled?

BrainStorm's Q1 2025 earnings call is scheduled for Monday, May 19, 2025, at 8:30 a.m. Eastern Time.

What is BrainStorm's (BCLI) main therapeutic platform?

BrainStorm's main therapeutic platform is NurOwn®, which uses autologous mesenchymal stem cells to produce neurotrophic factor-secreting cells for treating neurodegenerative diseases.

What clinical trials has BrainStorm (BCLI) completed?

BrainStorm has completed a Phase 3 trial in ALS and a Phase 2 open-label multicenter trial in progressive multiple sclerosis (MS).